High Tumor Control Rates Confirmed Even in Patients Unsuitable for Standard Treatments
Potential for Improved Survival Across All Stages, Including Advanced Liver Cancer
Single-Center Analysis of 2,000 Cases... Emerging as an Alternative for Liv

Samsung Medical Center has confirmed high tumor control and survival rates in a study analyzing the results of over 2,000 cases of proton therapy in liver cancer patients for whom standard treatments are difficult. The study demonstrated meaningful treatment outcomes even for patient groups where existing therapies pose challenges, suggesting the potential of proton therapy as a new alternative in liver cancer treatment.


On April 8, Samsung Medical Center announced that the research team led by Professors Park Heecheol and Yoo Jeongil, along with resident Lee Jeongha from the Department of Radiation Oncology, analyzed 2,000 cases of liver cancer treated with proton therapy. The results were published in the latest issue of the international journal, the European Journal of Cancer.

Samsung Medical Center Proves Effectiveness of Proton Therapy in Liver Cancer 'Treatment Blind Spots' View original image

Samsung Medical Center introduced a proton therapy system at the end of 2015 and, by September 2024, became the first in Korea to surpass 2,000 cases of proton therapy for liver cancer. This study reflects the outcomes of nearly 10 years of treating liver cancer patients with proton therapy.


The study included 1,823 patients (including those who underwent multiple treatments) who were considered to be in a "treatment blind spot" according to international liver cancer treatment guidelines. For these patients, standard treatments such as surgery or radiofrequency ablation were not possible or suitable due to the tumor's location, underlying liver function, comorbidities, or advanced age.


According to the analysis, among patients treated at Samsung Medical Center, the rate at which the target tumor did not recur or progress over two years after proton therapy was extremely high: 95.5% for patients at clinical stage BCLC 0 and 93.9% for BCLC A, both representing early-stage liver cancer. The rates were also high for more advanced stages, with 98.5% for BCLC B and 87.6% for BCLC C, where the cancer is progressing.


When the period was extended to three years, the non-recurrence or non-progression rates remained high: 91.1% for BCLC 0, 91.3% for BCLC A, 95% for BCLC B, and 83.3% for BCLC C. The overall survival rates over three years were also favorable compared to existing standard treatments: 81.1% for BCLC 0, 65.5% for BCLC A, 45.5% for BCLC B, and 37.2% for BCLC C.


The research team analyzed that, in order to overcome the limitations of existing liver cancer treatments, they established a multidisciplinary care system involving the departments of gastroenterology, surgery, radiology, hematology-oncology, radiation oncology, and pathology. After selecting appropriate patient groups, they were able to successfully establish proton therapy based on decades of experience in liver cancer radiation treatment.


According to the Samsung Medical Center medical staff, using their extensive experience with X-ray-based liver cancer radiation therapy, including respiratory gating technology, they utilized special four-dimensional CT scans before treatment to understand the movement of the tumor and organs. They also adjusted for real-time respiratory motion during treatment, enabling highly precise proton therapy.


Professor Yoo explained, "This research was possible by establishing the largest single-center cohort through standardized multidisciplinary collaboration and proton therapy protocols." He added, "Within the well-established system of the Samsung Medical Center Liver Cancer Center, proton therapy is becoming a key solution to address patients' unmet needs and improve prognosis."


Professor Park Heecheol, Director of the Proton Therapy Center, stated, "Proton therapy has become a definitive treatment alternative that can yield high local control and survival rates for liver cancer patients who are unsuitable for conventional treatments." He further remarked, "Its role is expected to expand further through future prospective studies."



As of 2025, the Proton Therapy Center at Samsung Medical Center has treated more than 8,183 patients in total, with the number of treatment procedures exceeding 100,000 cases.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing